mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation (EVEROLD)

This study has been completed.
Sponsor:
Collaborators:
Novartis
Roche Pharma AG
Genzyme, a Sanofi Company
Ministry of Health, France
Information provided by (Responsible Party):
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT01028092
First received: December 8, 2009
Last updated: July 7, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)